Lilly(US:LLY) Sou Hu Cai Jing·2026-01-31 11:12Core Viewpoint - Tyligand Bioscience has submitted its listing application to the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [3]. Company Overview - Tyligand Bioscience, established in 2017, is a clinical-stage biopharmaceutical company focused on discovering and developing innovative cancer therapies [4]. - The company holds 97 patents and patent applications, including 25 related to its core product TSN1611 [4]. - Tyligand has not yet received any marketing approval for its candidate drugs and has not generated any revenue from product sales [4]. - The company is headquartered in Suzhou and employs a total of 64 staff, with 49 in research and development [4]. Shareholding Structure - Key shareholders include Dr. Tony Yantao Zhang, Dr. Boyu Zhong, Dr. Zhong-Yin Zhang, and Tyligand Holdings, collectively holding 24.01% of the issued shares [4]. - Dr. Tony Yantao Zhang directly holds approximately 0.35%, while Tyligand Holdings holds about 23.66%, with ownership distributed among the founders [4]. Management Team - Dr. Tony Yantao Zhang, 64, is the Chairman and CEO, responsible for overall management and strategic planning [5]. - Dr. Boyu Zhong, 63, serves as the Executive Director and President, leading research and development efforts [6]. Financial Performance - The company's revenue for 2023, 2024, and the first nine months of 2025 is projected to be 7.856 million, 1.506 million, and 11.358 million respectively, with losses of 70.461 million, 28.354 million, and 123 million [7]. - Revenue sources include providing research and development services and intellectual property licensing [7].